Pharmaceutical companies and health care providers can access specialized AI models

Ben Wodecki, Jr. Editor

March 21, 2024

2 Min Read
Online doctor and medical consultation. Pharmaceutical research laboratory with scientists working to develop new drugs and genetic testing
Getty Images

Nvidia has launched a series of services designed to improve productivity workflows in the health care industry.

The 25 microservices, launched at Nvidia’s GTC AI conference this week, are designed to assist pharmaceutical companies, doctors and hospitals in introducing generative AI solutions.

Researchers and medical practitioners can integrate the AI microservices into new and existing applications and run them anywhere — from the cloud to in-house.

The suite contains solutions that could help with drug discovery, gather better patient data for early disease detection and implement smarter digital assistants.

It includes access to specialized AI models including ESMFold for protein structure prediction and DiffDock which helps researchers understand how drug molecules interact with targets.

Also included are software development kits including NeMo, the model development platform, and Parabricks, a software suite for performing analysis of DNA sequences.

“For the first time in history, we can represent the world of biology and chemistry in a computer, making computer-aided drug discovery possible,” said Kimberly Powell, Nvidia’s vice president of health care.. “By helping health care companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”

Related:Nvidia Unveils Blackwell GPUs to Power Massive AI Models

Nvidia said nearly 50 firms are already using its health care microservices, including Amgen and medical imaging software maker V7.

"Generative AI is transforming drug discovery by allowing us to build sophisticated models and seamlessly integrate AI into the antibody design process,” said David M. Reese, Amgen’s executive vice president and CTO. “Our team is harnessing this technology to create the next generation of medicines that will bring the most value to patients.”

About the Author(s)

Ben Wodecki

Jr. Editor

Ben Wodecki is the Jr. Editor of AI Business, covering a wide range of AI content. Ben joined the team in March 2021 as assistant editor and was promoted to Jr. Editor. He has written for The New Statesman, Intellectual Property Magazine, and The Telegraph India, among others. He holds an MSc in Digital Journalism from Middlesex University.

Keep up with the ever-evolving AI landscape
Unlock exclusive AI content by subscribing to our newsletter!!

You May Also Like